These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2568340)

  • 1. Sulphasalazine desensitisation.
    Mittal PK; Goyal KK; Gulati R; Jain P; Singh GP
    Indian J Gastroenterol; 1989 Jul; 8(3):204-5. PubMed ID: 2568340
    [No Abstract]   [Full Text] [Related]  

  • 2. Mild ulcerative colitis.
    Maitra AK
    Br Med J; 1970 Feb; 1(5693):431. PubMed ID: 4392199
    [No Abstract]   [Full Text] [Related]  

  • 3. Sulphasalazine retention enemas in ulcerative colitis.
    Serebro HA; Kay S
    Br Med J (Clin Res Ed); 1981 Jul; 283(6284):144-5. PubMed ID: 6114768
    [No Abstract]   [Full Text] [Related]  

  • 4. Folate levels in patients with ulcerative colitis receiving sulphasalazine.
    Schoeman M; Bezuidenhout DJ
    S Afr Med J; 1984 Sep; 66(11):415. PubMed ID: 6148790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hypersensitivity reaction to sulfasalazine with a clinical picture similar to mononucleosis].
    Foresti V; Tronci M; Ungaro A; Confalonieri F
    Recenti Prog Med; 1988 Sep; 79(9):382-3. PubMed ID: 2904684
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of disodium cromoglycate and sulphasalazine as maintenance therapy for ulcerative colitis.
    Willoughby CP; Heyworth MF; Piris J; Truelove SC
    Lancet; 1979 Jan; 1(8108):119-22. PubMed ID: 84148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects.
    Di Paolo MC; Paoluzi OA; Pica R; Iacopini F; Crispino P; Rivera M; Spera G; Paoluzi P
    Dig Liver Dis; 2001 Oct; 33(7):563-9. PubMed ID: 11816545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulphasalazine desensitisation.
    Holdsworth CD
    Br Med J (Clin Res Ed); 1981 Jan; 282(6258):110. PubMed ID: 6109553
    [No Abstract]   [Full Text] [Related]  

  • 9. Sulphasalazine rectal enemas: topical method of inducing remission of active ulcerative colitis affecting rectum and descending colon.
    Serebro H; Kay S; Javett S; Abrahams C
    Br Med J; 1977 Nov; 2(6097):1264. PubMed ID: 22378
    [No Abstract]   [Full Text] [Related]  

  • 10. Sulphasalazine retention enemas in ulcerative colitis: a double-blind trial.
    Palmer KR; Goepel JR; Holdsworth CD
    Br Med J (Clin Res Ed); 1981 May; 282(6276):1571-3. PubMed ID: 6113021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proceedings: A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (salazopyrin).
    Dissanayake AS; Truelove SC
    Gut; 1973 Oct; 14(10):818. PubMed ID: 4148469
    [No Abstract]   [Full Text] [Related]  

  • 12. Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis.
    Cowan GO; Das KM; Eastwood MA
    Br Med J; 1977 Oct; 2(6094):1057-9. PubMed ID: 21720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.
    Azad Khan AK; Howes DT; Piris J; Truelove SC
    Gut; 1980 Mar; 21(3):232-40. PubMed ID: 6105118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial: Sulphasalazine-induced lung disease.
    Lancet; 1974 Aug; 2(7879):504-5. PubMed ID: 4136679
    [No Abstract]   [Full Text] [Related]  

  • 15. The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine.
    Donald IP; Wilkinson SP
    Postgrad Med J; 1985 Dec; 61(722):1047-8. PubMed ID: 2869480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis.
    Andreoli A; Spinella S; Levenstein S; Prantera C
    Ital J Gastroenterol; 1994 Apr; 26(3):121-5. PubMed ID: 7914759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
    Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
    Gut; 1988 May; 29(5):669-74. PubMed ID: 2899536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease.
    Korelitz BI; Present DH; Rubin PH; Fochios SE
    J Clin Gastroenterol; 1984 Feb; 6(1):27-31. PubMed ID: 6142067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of the acetylator phenotype on the metabolism of sulphasalazine in man.
    Azad Khan AK; Nurazzaman M; Truelove SC
    J Med Genet; 1983 Feb; 20(1):30-6. PubMed ID: 6133000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of serum concentrations of sulphasalazine and some of its metabolites after therapy by the oral or rectal route.
    Ashworth M; Arthur M; Turmer AD; Smith PR
    Pharmatherapeutica; 1984; 3(8):551-5. PubMed ID: 6142465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.